Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma

The role of the epidermal growth factor receptor (EGFR) mutation status testing in lung squamous cell carcinoma (SqCC) remains controversial. Evidence of the effectiveness of osimertinib in SqCC with EGFR T790M mutation is limited. Here, we describe a hitherto unreported case of a stage III SqCC pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, MuYun, Wen, QiuYuan, Wu, Xia, Yu, FengLei, Liu, WenLiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471018/
https://www.ncbi.nlm.nih.gov/pubmed/32667739
http://dx.doi.org/10.1111/1759-7714.13431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471018/
https://www.ncbi.nlm.nih.gov/pubmed/32667739
http://dx.doi.org/10.1111/1759-7714.13431

Ejemplares similares